Efficacy and Safety of VMX Eye Drops for Dry Eye Disease

Inclusion Criteria: * Patients with an age of ≥ 18 and ≤ 80 years * Patients with a diagnosis of Dry Eye (mild/moderate) with at least one of the following: * Tear Osmolarity \>308 mOsm/L * TBUT \< 10 seconds * Schirmer I test ≥ 5 mm and ≤ 14 mm at 5 minutes * Patients not treated with artificial tears for at least 7 days * Patients not treated with artificial tears for at least 7 days Exclusion Criteria: * Use of systemic medications which may affect a dry eye condition within 1 month prior to study enrolment (e.g. low-dose aspirin, antihistamines, decongestants, antipsychotics, parkinsonism medications, anticholinergics, oral isotretinoin, and oral diazepam) * Patients with a score of ≤ 4 mm at 5 minutes on the Schirmer I test * Patients that suffer of ocular allergy pathology (seasonal and chronic) * Ongoing ocular or systemic infectious conditions * Use of topical ocular therapies that cannot be suspended for the entire duration of the study * Use of topical antibiotics and or corticosteroids within 15 days prior to study enrolment * Use of systemic antibiotics and or corticosteroids within 1 month prior to study enrolment * Any intraocular surgery in the past 12 months or require any intraocular surgery during the study * Acute and Chronic Conjunctival Disease * Eyelid surgery within the 6 months prior to study enrolment * Presence of congenitally absent lacrimal or Meibomian glands or have any obstructive disease of the lacrimal glands * History of ocular herpetic keratitis or active blepharitis in the 4 weeks prior to study enrolment * History of autoimmune diseases * Inflammations or abnormalities in the eyelid, in accordance with PI's clinical judgment * History of corneal diseases, as keratoconus * History of corneal transplant in one or both eyes * Keratinization of the eyelid margin * History of Sjögren's syndrome * History of corneal trauma in the last 4 weeks prior to study enrolment * Patients who are unwilling to discontinue all artificial tears and use only the study product ad indicated for the duration of the study * Inability to self-administer study medications * Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study. * Any hypersensitivity to the use of the study product formulations or an allergy to any ingredients contained within product formulation * Participation in other clinical studies involving drugs or devices within 30 days prior to study enrolment. * Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial * Patients unable or unwilling to comply with appointments or all protocol requirements